查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1555712

注射奈米药物市场，按产品类型、治疗领域、给药途径、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Injectable Nanomedicines Market, By Product Type, By Therapeutic Area, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 388 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年註射奈米药物市场规模为6.5456亿美元，2024年至2032年复合年增长率为8.3%。

注射奈米药物市场-市场动态

慢性病的日益普及推动了对注射奈米药物的需求

癌症、糖尿病、心血管疾病和自体免疫疾病等慢性病的盛行率不断上升，推动了对创新治疗方法的需求，包括注射奈米药物。可注射的奈米药物可以设计用于将药物专门输送到患病组织或细胞，从而减少对健康组织的副作用。美国食品药物管理局 (FDA) 在塑造注射奈米药物市场方面发挥关键作用。 FDA 严格的审批流程确保了这些创新疗法的安全性和有效性，但也为寻求市场进入的公司带来了挑战。奈米药物可以提供受控和持续的药物释放，这对于治疗慢性疾病至关重要。这有助于长期维持治疗药物水平，减少注射频率并提高患者依从性。据世界卫生组织(WHO)称，在印度，21%的老年人患有至少一种慢性病，其中农村地区为17%，城市地区为29%。在美国，近 95% 的 60 岁及以上成年人至少患有一种慢性病，近 80% 的人患有两种或两种以上。

注射奈米药物市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 8.3% 左右的复合年增长率成长

根据产品类型细分，预计聚合物奈米粒子将在 2023 年显示最大的市场份额

根据治疗领域细分，肿瘤学是2023年的主导类型

根据最终用户细分，医院是 2023 年的主导类型

按地区划分，北美是 2023 年的主要收入来源

注射奈米药物市场-細項分析：

全球注射奈米药物市场根据产品类型、治疗领域、给药途径、最终用户和地区进行细分。

根据产品类型，市场分为五类：脂质体、聚合物奈米颗粒、金属奈米颗粒、树枝状聚合物和胶束。在整个预测期内，预计对聚合物奈米颗粒的需求将进一步增加，这种需求在过去几年中已显着增长。奈米技术 (NP) 透过将科学极限推向奈米医学产业革命性发现的前沿，正在影响癌症、神经系统疾病和心血管疾病等学科。亚太地区政府在奈米医学研发（R&D）的目标是成为该领域的领导者并解决某些社会需求。

根据应用，市场分为四类：医院、诊所、研究实验室和其他。可注射的奈米药物可以被设计为将药物直接输送到特定的细胞或组织，例如靶向癌细胞，同时保护健康细胞。这种精确度减少了副作用并提高了治疗效果。奈米药物可以根据患者的个别需求进行定制，从而製定更个人化和有效的治疗计划。这对于治疗癌症等复杂疾病特别有益。

注射奈米药物市场 - 地理洞察

从地理位置来看，北美和欧洲由于强大的研究基础设施和支持性监管框架而处于领先地区。然而，由于医疗保健投资的增加和先进医疗技术的采用，亚太地区的新兴市场正在快速成长。由于其强大的医疗基础设施、广泛的研发能力和先进医疗技术的高度采用，北美是注射奈米药物市场的重要参与者。美国在该地区处于领先地位，这得益于奈米技术研究的强劲资金以及重要製药和生物技术公司的强大影响力。癌症、糖尿病和心血管疾病等慢性疾病的高盛行率也支持了该市场，这需要奈米药物等先进的治疗选择。欧洲药品管理局 (EMA) 是监督该地区奈米药物审批和商业化的主要监管机构。 EMA 的法规通常被认为是严格的，但它们为公司开发和销售奈米药物提供了明确的框架。欧盟的倡议，例如「地平线2020」计划，在支持奈米医学研究和创新方面也发挥了至关重要的作用。

注射奈米药物市场-竞争格局：

注射奈米药物市场的主要参与者包括辉瑞公司、阿斯特捷利康公司、赛诺菲公司、强生公司、Moderna公司、诺华公司等。以加速开发和应用。辉瑞利用合作伙伴关係和收购来增强其註射奈米药物产品组合，重点关注脂质体製剂和基于奈米颗粒的疗法。诺华在研发方面投入巨资，并与学术机构合作开发下一代奈米药物，特别是在标靶药物传输方面。百时美施贵宝公司强调奈米技术来增强其生物製剂的交付，特别是在肿瘤学领域，拥有强大的奈米药物候选产品管线。阿斯特捷利康利用奈米技术进行标靶药物输送，特别是在肿瘤学领域，并投资于伙伴关係和合作以扩大其奈米医学能力。

最新进展：

2021 年 3 月，PACIRA Biosciences, Inc. 的 Exparel（布比卡因脂质体注射混悬液）获得 FDA 批准，这是一种用于儿科患者的新药物应用。

2021年3月，Jazz Pharmaceutical 宣布追加 Vyxeos（柔红霉素和阿糖胞苷）用于治疗继发性急性骨髓性白血病。

目录

第一章：注射奈米药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按产品类型分類的注射奈米药物市场片段
    • 按治疗领域分類的注射奈米药物市场片段
    • 依给药途径分類的注射奈米药物市场片段
    • 最终用户的注射奈米药物市场片段
    • 按国家/地区分類的注射奈米药物市场片段
    • 按地区分類的注射奈米药物市场片段
  • 竞争洞察

第 3 章：注射奈米药物主要市场趋势

  • 注射奈米药物市场驱动因素
    • 市场驱动因素的影响分析
  • 注射奈米药物市场限制
    • 市场限制影响分析
  • 注射奈米药物市场机会
  • 注射奈米药物市场未来趋势

第 4 章：注射奈米药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：注射奈米药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：注射奈米药物市场格局

  • 2023 年註射奈米药物市场份额分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：注射奈米药物市场 - 按产品类型

  • 概述
    • 按产品类型分類的细分市场占有率分析
    • 脂质体
    • 聚合物奈米颗粒
    • 金属奈米粒子
    • 树枝状聚合物
    • 胶束

第 8 章：注射奈米药物市场 - 依治疗领域

  • 概述
    • 按治疗领域分類的细分市场占有率分析
    • 肿瘤学
    • 心血管疾病
    • 神经系统疾病
    • 传染病
    • 自体免疫疾病

第 9 章：注射奈米药物市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 静脉 (IV) 注射
    • 皮下注射
    • 肌肉内注射
    • 鞘内注射

第 10 章：注射奈米药物市场 - 按最终用户

  • 概述
    • 按治疗领域分類的细分市场占有率分析
    • 医院
    • 诊所
    • 研究实验室
    • 其他的

第 11 章：注射奈米药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美注射奈米药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按产品类型）
    • 北美市场规模与预测（按治疗领域）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲注射奈米药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按产品类型）
    • 欧洲市场规模与预测（按治疗领域）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区注射奈米药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（依产品类型）
    • 按治疗领域分類的亚太市场规模和预测
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲注射奈米药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按产品类型）
    • 拉丁美洲市场规模与预测（按治疗领域）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲注射奈米药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按产品类型）
    • 中东和非洲市场规模及预测（按治疗领域）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析 - 注射奈米药物产业

  • 竞争仪表板
  • 公司简介
    • Pfizer Inc.
    • AstraZeneca PLC
    • Johnson & Johnson
    • Sanofi
    • Merck & Co., Inc.
    • Moderna, Inc.
    • Amgen Inc.
    • Novartis AG
    • F. Hoffmann-La Roche AG
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb
    • Teva Pharmaceutical Industries Ltd.
    • Nanobiotix SA
    • CytImmune Sciences, Inc.
    • BIND Therapeutics, Inc.
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV3689

REPORT HIGHLIGHT

Injectable Nanomedicines Market size was valued at USD 654.56 million in 2023, expanding at a CAGR of 8.3% from 2024 to 2032.

The Injectable Nanomedicines market involves the development, production, and commercialization of nanoscale drugs that are administered via injection. These nanomedicines leverage the unique properties of nanoparticles to enhance drug delivery, targeting, and efficacy, particularly in treating diseases such as cancer, cardiovascular disorders, and infectious diseases. Key drivers of the market include advancements in nanotechnology, increased prevalence of chronic diseases, and the demand for targeted therapies that reduce side effects. Additionally, government support for nanomedicine research and development, along with growing investments from pharmaceutical companies, is propelling market growth. Challenges in the market include high production costs, regulatory complexities, and potential safety concerns related to the long-term effects of nanoparticles on the human body. Despite these hurdles, the market is expected to grow significantly due to the increasing number of nanomedicine products in the pipeline and their promising therapeutic outcomes.

Injectable Nanomedicines Market- Market Dynamics

The increasing prevalence of chronic diseases driving the need for injectable nanomedicines

The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders is driving the need for innovative treatment approaches, including injectable nanomedicines. Injectable nanomedicines can be designed to deliver drugs specifically to diseased tissues or cells, reducing the side effects on healthy tissues. The U.S. Food and Drug Administration (FDA) plays a pivotal role in shaping the injectable nanomedicine market. The FDA's stringent approval process ensures the safety and efficacy of these innovative therapies, but it also poses a challenge for companies seeking market entry. Nanomedicines can provide controlled and sustained drug release, which is critical for managing chronic diseases. This helps in maintaining therapeutic drug levels over an extended period, reducing the frequency of injections and improving patient compliance. According to the World Health Organization (WHO), In India, 21% of the elderly have at least one chronic disease, with 17% in rural areas and 29% in urban areas. In the US, nearly 95% of adults 60 and older have at least one chronic condition, and nearly 80% have two or more.

Injectable Nanomedicines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.3% over the forecast period (2024-2032)

Based on product type segmentation, Polymeric Nanoparticles were predicted to show maximum market share in the year 2023

Based on Therapeutic Area segmentation, Oncology was the leading type in 2023

Based on End User segmentation, Hospitals were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Injectable Nanomedicines Market- Segmentation Analysis:

The Global Injectable Nanomedicines Market is segmented based on Product Type, Therapeutic Area, Route of Administration, End User, and Region.

The market is divided into five categories based on product type: Liposomes, Polymeric Nanoparticles, Metal Nanoparticles, Dendrimers, and Micelles. Throughout the projection period, there is expected to be a further increase in demand for polymeric nanoparticles, which has grown significantly in the last few years. Nanotechnology (NP) is influencing disciplines such as cancer, neurological disorders, and cardiovascular diseases by pushing scientific limits to the forefront of revolutionary discoveries for the nanomedicine business. The goal of the Asia Pacific government's research and development (R&D) in nanomedicine is to be a leader in the field and to solve certain social requirements.

The market is divided into four categories based on application: Hospitals, Clinics, Research Laboratories, and Others. Injectable nanomedicines can be engineered to deliver drugs directly to specific cells or tissues, such as targeting cancer cells while sparing healthy ones. This precision reduces side effects and increases treatment efficacy. Nanomedicines can be tailored to the individual patient's needs, allowing for more personalized and effective treatment plans. This can be particularly beneficial in treating complex diseases like cancer.

Injectable Nanomedicines Market- Geographical Insights

Geographically, North America and Europe are leading regions due to robust research infrastructure and supportive regulatory frameworks. However, emerging markets in Asia-Pacific are witnessing rapid growth due to increasing healthcare investments and the adoption of advanced medical technologies. North America is a significant player in the injectable nanomedicines market, driven by its strong healthcare infrastructure, extensive R&D capabilities, and high adoption of advanced medical technologies. The United States leads the region, supported by robust funding for nanotechnology research and a strong presence of key pharmaceutical and biotech companies. The market is also bolstered by a high prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions, which necessitate advanced therapeutic options like nanomedicines. The European Medicines Agency (EMA) is the primary regulatory body overseeing the approval and commercialization of nanomedicines in the region. The EMA's regulations are often seen as rigorous, but they provide a clear framework for companies to develop and market nanomedicines. The European Union's initiatives, such as the Horizon 2020 program, have also played a crucial role in supporting nanomedicine research and innovation.

Injectable Nanomedicines Market- Competitive Landscape:

Major players in the Injectable Nanomedicines Market include Pfizer Inc., AstraZeneca PLC, Sanofi, Johnson & Johnson, Moderna, Inc., Novartis AG etc. Companies are increasingly collaborating with academic institutions, research organizations, and other pharmaceutical companies to accelerate the development and commercialization of nanomedicines. Pfizer leverages partnerships and acquisitions to enhance its injectable nanomedicine portfolio, focusing on liposomal formulations and nanoparticle-based therapies. Novartis invests heavily in R&D and collaborates with academic institutions to develop next-generation nanomedicines, particularly in targeted drug delivery. Bristol-Myers Squibb Company emphasizes nanotechnology to enhance the delivery of its biologics, particularly in oncology, with a strong pipeline of nanomedicine candidates. AstraZeneca uses nanotechnology for targeted drug delivery, particularly in oncology, and invests in partnerships and collaborations to expand its nanomedicine capabilities.

Recent Developments:

In March 2021, PACIRA Biosciences, Inc. Got FDA Approval For Exparel (Bupivacaine Liposome Injectable Suspension) Which Is A New Drug Application In Pediatric Patients.

In March 2021, Jazz Pharmaceutical Announced Additional Vyxeos (Daunorubicin And Cytarabine) For The Treatment Of Secondary Acute Myeloid Leukemia.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INJECTABLE NANOMEDICINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Sanofi
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Amgen Inc.
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb
  • Teva Pharmaceutical Industries Ltd.
  • Nanobiotix SA
  • CytImmune Sciences, Inc.
  • BIND Therapeutics, Inc.
  • Others

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Liposomes
  • Polymeric Nanoparticles
  • Metal Nanoparticles
  • Dendrimers
  • Micelles

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY THERAPEUTIC AREA - MARKET ANALYSIS, 2019 - 2032

  • Oncology
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Autoimmune Diseases

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous (IV) Injection
  • Subcutaneous Injection
  • Intramuscular Injection
  • Intrathecal Injection

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Research Laboratories
  • Others

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Injectable Nanomedicines Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Injectable Nanomedicines Market Snippet by Product Type
    • 2.1.2. Injectable Nanomedicines Market Snippet by Therapeutic Area
    • 2.1.3. Injectable Nanomedicines Market Snippet by Route of Administration
    • 2.1.4. Injectable Nanomedicines Market Snippet by End User
    • 2.1.5. Injectable Nanomedicines Market Snippet by Country
    • 2.1.6. Injectable Nanomedicines Market Snippet by Region
  • 2.2. Competitive Insights

3. Injectable Nanomedicines Key Market Trends

  • 3.1. Injectable Nanomedicines Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Injectable Nanomedicines Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Injectable Nanomedicines Market Opportunities
  • 3.4. Injectable Nanomedicines Market Future Trends

4. Injectable Nanomedicines Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Injectable Nanomedicines Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Injectable Nanomedicines Market Landscape

  • 6.1. Injectable Nanomedicines Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Injectable Nanomedicines Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Liposomes
    • 7.1.3. Polymeric Nanoparticles
    • 7.1.4. Metal Nanoparticles
    • 7.1.5. Dendrimers
    • 7.1.6. Micelles

8. Injectable Nanomedicines Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 8.1.2. Oncology
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Neurological Disorders
    • 8.1.5. Infectious Diseases
    • 8.1.6. Autoimmune Diseases

9. Injectable Nanomedicines Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Intravenous (IV) Injection
    • 9.1.3. Subcutaneous Injection
    • 9.1.4. Intramuscular Injection
    • 9.1.5. Intrathecal Injection

10. Injectable Nanomedicines Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Clinics
    • 10.1.4. Research Laboratories
    • 10.1.5. Others

11. Injectable Nanomedicines Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Injectable Nanomedicines Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Injectable Nanomedicines Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Injectable Nanomedicines Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Injectable Nanomedicines Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Injectable Nanomedicines Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Injectable Nanomedicines Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Pfizer Inc.
    • 12.2.2. AstraZeneca PLC
    • 12.2.3. Johnson & Johnson
    • 12.2.4. Sanofi
    • 12.2.5. Merck & Co., Inc.
    • 12.2.6. Moderna, Inc.
    • 12.2.7. Amgen Inc.
    • 12.2.8. Novartis AG
    • 12.2.9. F. Hoffmann-La Roche AG
    • 12.2.10. Gilead Sciences, Inc.
    • 12.2.11. Bristol-Myers Squibb
    • 12.2.12. Teva Pharmaceutical Industries Ltd.
    • 12.2.13. Nanobiotix SA
    • 12.2.14. CytImmune Sciences, Inc.
    • 12.2.15. BIND Therapeutics, Inc.
    • 12.2.16. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us